Anti-Aging Therapeutics Volume XIII. A4M American Academy
a cofactor with cancer patients. B-Sit reduces insulin resistance (most likely by restoring membrane function, especially selective permeability) and regulates insulin production through several mechanisms, one of which is by supporting normal cholesterol homeostasis. In addition, curcumin inhibits cell membrane cholesterol accumulation, furthering the effects of B-Sit, via a different mechanism.
An ideal curcumin will be naturally absorbed, maintain effective serum levels for at least 12-hours in order to allow for 24-hour effective blood levels without frequent dosing, and store in the liver for release throughout the day. In this way, doses of as little as 1,000 mg to 4,000 mg are recommended.
Coenzyme Q10 and the B-Sit/AOX Matrix
There are a number of key reasons why CoQ10 should always be included in the Matrix. Firstly, it is essential for proper cell reproduction. Secondly, it has been shown that when the circumstances for metastases are set up, the process is not triggered if there is adequate CoQ10 present. CoQ10 has been demonstrated to reduce IL-8 to normal levels. As noted above, IL-8 is the primary inflationary mechanism that drives the formation and survival of tumor cells for all cancers. Reducing IL-8 also works with the other components of the Matrix to reduce angiogenesis. The efficiency of CoQ10’s function in the cell membrane and for overall cell function is restored in cancer cells through the reestablishment of membrane elasticity and permeability by B-Sit.
An ideal CoQ10 is highly absorbable – 100% of what is supplemented needs to be available for absorption. The circulating CoQ10 needs to be readily able to cycle from the ubiquinone to ubiquinol, and be orthomolecular in nature, thus allowing it to be cellularly-bioavailable. Preferably, the CoQ10 used should have a long clinical track record and have demonstrated research efficacy. The recommended dose range is 300 to 800 mg/day.
Using B-Sit/AOX Matrix Nutrition
The above forms the basis for the nutritional support we use. As appropriate for each individual, a more complete program is developed including: vitamin D3 to bring the D3 levels to 65 - 90 ng/ml; mixed tocopherols with high gamma-tocopherol (taken in the morning) and 125 to 500 mgs of a high-delta-tocotrienol supplement taken in the evening; a balanced calcium and magnesium supplement; vitamin K2; vitamin B Complex; and 5 grams of vitamin C.
Given that the basis of the Matrix is to restore essential missing nutrients, it can be used in a general nutrition program, during treatment, and for anyone who has developed cancer as life-long maintenance nutrition.
CONCLUDING REMARKS
Monitoring and Follow-Up
The nutritional program outlined above, the B-Sit/AOX Matrix, has been used for over 5-years, and the results reported in the first section are based on this use. Visually, this can be seen in Figure 1, which shows imaging results of the same prostate, initially diagnosed as a Gleason 7 (image a) and upon a follow-up examine after daily use of the above supplement regime (image b).
The results shown in Figure 1 illustrate both the efficacy of restoring fundamental nutritional support that has been systematically removed from our diets by alterations in the food supply, and the need for a means to monitor, on a regular basis, each individual’s response to treatment. Given the number of factors involved in nutritional support, this is the only way to know that this individual’s body is capable of restoring its anti-cancer functions. The same monitoring approach can be applied to any therapeutic intervention, especially since the 3-D sonogram is not compromised by the treatment itself.
Figure 1. Prostate cancer subject treated with B-Sit/AOX supplement program. a) DCE-MRI of Gleason 7 non-palpable prostate cancer (yellow arrow), (vascular enhancement is red), b) Post treatment scan of same area showing disappearance of vascular enhancement.
When establishing a monitoring schedule for an individual, two additional areas need to be kept in mind, interval cancers and evaluating successful treatment. The concept of fast growing cancers called “interval cancers” has led to routine biannual screening of male and female high risk patients. It is recognized that mammography misses invasive breast cancers with great frequency, so there is a half-year time period in which health conscious women should alert themselves to the possibility of early breast cancer as they routinely undergo ultrasound breast screening twice a year. In practice, about 5% of men develop aggressive interval cancers within half a year from their last normal or stable evaluation. A presentation entitled “Interval Cancers of the Prostate: Evaluation By 3-T MRI and 3-D Power Doppler Ultrasound” was made at the 2009 meeting of the Societe Francaises de Radiologie in Paris demonstrating that new aggressive tumors may occur more rapidly than clinically expected and may, in part, explain the failure of certain treatments.
When a man has not had a biopsy or has had a negative biopsy and a vascular tumor is demonstrated on the 3-D PDS, an MRI exam is recommended, which shows the prostate gland, the capsule of the prostate, the regional lymph glands, seminal vesicles, and boney pelvis. Other bones, to which cancer frequently spreads, such as the lower spine and hip, may also be imaged for abnormalities. While the MRI exam is not as good an indicator of cancer aggression, it shows spread of the tumor outside the prostate capsule to the lymph nodes better then the 3-D PDS and better than the CT scan, which is currently used as the standard test for staging.
Assessing Response to Prostate Cancer Therapy
The value of medical imaging is to:
•Localize the volume of disease including extracapsular extension.
•Assess bone metastases, seminal vesicle invasion, and lymphadenopathy.
•Estimate degree of aggressivity (similar to Gleason grading).
•Determine efficacy of therapy.
•Monitor changes.
•Tailor future therapy.
•Determine tumor recurrence.
•Identify new tumors.
One of the problems of evaluating cancer treatment is that the tumor may be rendered harmless or even dead but the volume of the tumor remains the same or even enlarges. That is, the cancer cells may be killed off and scar tissue replaces the dead cells, leaving the size of the original malignancy unchanged, or edema and necrotic fluid buildup enlarge the region simulating tumor growth. This lesson was learned 19-years ago in treating liver tumors. The therapy would render the cancer harmless, but the size of the mass on the isotope scans, sonogram, CT, and MRI would remain unchanged or even enlarge. The same is true of some PCa’s that are inactivated but still feel like cancer on the digital rectal exam and show a mass effect on the sonogram and MRI. There needs to be a way to monitor changes and determine the efficacy of treatment. Fortunately, the blood flows in malignancies that have been inactivated decrease or disappear and can be quickly and accurately measured in the moment. Thus, with 3-D PDS there is a simple tool to quantify blood flow patterns to demonstrate therapeutic response.
REFERENCES
1.Ewing J. Neoplastic Diseases. London: WB Saunders; 1940.
2.Lassau N, Koscielny S, Avril M, Margulis A, Duvillard P, Baere T, Roche A, Leclere J. Prognostic value of angiogenesis evaluated with high frequency and color Doppler sonography for preoperative assessment of melanomas. AJR Am J Roentgenol. 2002;178;1547-1551.
3.Cornud F, Hamida K, Flam T, Helenon O, Chretien Y, Thiounn N, Correas J, Casanova J, Moreau J. Endorectal color Doppler sonography and endorectal MR imaging features of non palpable prostate cancer. AJR Am J Roentgenol. 2000;175;1161-1168.
4.Bard R. Dynamic Contrast Enhanced MRI of Prostate Cancer. New York, NY: Springer; 2009.
5.Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical Activity and Survival After Prostate Cancer Diagnosis in the